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Abstract
Introduction: Hypertonic sodium chloride solutions and liposomal drugs with pulmotropic effect are of great interest 
for the treatment of acute lung injury (ALI). The results of the studies on the efficacy of hypertonic solutions and lipo-
somes in ALI treatment are currently controversial.
Materials and methods: For the experiment, liposomes with dexamethasone, N-acetylcysteine (NAC), aprotinin and 
dye Cyanine-7 (Cy-7) were obtained. A liposome analysis was performed by means of spectrophotometry. ALI was 
modeled in rats by the administration of the damaging agents into the trachea. The experimental agents were injected 
once intravenously after the modeling of ALI. For experimental therapy used liposomal agents, 7.5% hypertonic saline 
(HS) and HyperHAES solutions in the respective groups. The efficacy of the therapy was assessed by the survival of 
animals, functional indicators of the cardiovascular and respiratory systems, and by the lung-body ratio. The biodistri-
bution of liposomes after intravenous administration was investigated in mice through using a fluorescent dye Cy-7. 
The biodistribution of liposomes with Cy-7 was assessed using bioimaging according to the fluorescence intensity of 
internal organs (lungs, liver, and kidneys) and blood, expressed as dye concentration according to the calibration de-
pendence of dye concentrarion on fluorescence intensity.
Results and discussion: All the studied liposomal drugs were effective for the pharmacological correction of ALI. 
Hypertonic solutions, unlike liposomal drugs, were less likely to prevent the development of pulmonary edema. All the 
studied therapeutic agents increased the survival rate of the laboratory animals with ALI. The most effective experimen-
tal agent was liposomal dexamethasone. The use of drugs in form of simple liposomes with average diameter of 350 nm 
provided for a higher concentration of the drug in the lungs within the first 40 minutes after intravenous administration.
Conclusion: Intravenous administration of liposomal forms is promising for the pharmacotherapy of acute lung injury.
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Introduction
Among the direct causes of acute lung injury (ALI), the 
most common one is the aspiration of various exogenous 
and endogenous substances (stomach contents) into the 
lower airways (Avdeev 2008).
Interest towards hypertonic saline (HS) of sodium 
chloride, as an anti-edematous and anti-inflammatory 
agent in acute lung injury has appeared only recently (Fo-
minsky 2013). The therapeutic effect of HS in ALI was 
shown in cell culture and in vivo experiments, and it was 
associated with the suppression of neutrophil activation 
(Holms et al. 2015). The mechanism of HS action in case 
of ALI is associated with inhibition of neutrophil respon-
ses (chemotaxis, phagocytosis, etc.) (Inoue et al. 2011). 
Unlike colloids, hypertonic sodium chloride solution has 
an advantage that the limited volume of liquid is injec-
ted, and the alveolar-capillary barrier is increased. But the 
data about this remains controversial (Bulger et al. 2011, 
Roch et al. 2013). In addition, the effectiveness of the 
combination of HS sodium chloride with hydroxyethyl 
starch (HES) solutions as a means to prevent impairments 
of the oxygenating function of the lungs and to improve 
oxygen delivery to tissues is confirmed (Yu et al. 2012a). 
The combination of HS and HES inhibits neutrophil ad-
hesion to the endothelium and reduces the production of 
interleukins when administered intravenously (Safdar et 
al. 2005, Yu et al. 2012a). Recent studies have shown an 
increasing interest towards hyperosmolar solutions in 
which plasma hyper osmolarity and hypernatriemia are 
assessed as factors contributing to the therapeutic effect 
in ALI (Bihari et al. 2016).
Liposomes are well-studied drug carriers. They allow 
encapsulating both hydrophilic and lipophilic substances 
(Bhardwaj and Burgess 2010). They have a shell – an ar-
tificial membrane – and are used for the selective delivery 
of therapeutic drugs into various tissues for create there an 
effective concentration of drug (Baryshnikov 2012). The 
relative ease of including therapeutic agents in liposomes, 
the possibility of direct delivery of liposomes to the ap-
propriate part of the body, the relative non-immunogeni-
city, and low toxicity made liposomes very appealing for 
drug delivery to the lungs (Bailey and Berkland 2009). To 
have liposomal dosage forms target lungs, the so-called 
“vascular targeting” strategy can be used (Carnemolla et 
al. 2013). This experimental strategy allows delivery insi-
de or through endothelial cells (Guo et al. 2014).
When studying the biodistribution of simple liposomes 
in damaged lungs, they were found to accumulate diffe-
rently in healthy and affected areas due to the different in-
tensity of blood flow and damage to the capillaries (Bren-
ner et al. 2018). To confirm the significant influence of 
size on liposome accumulation in lungs, there are relevant 
studies on ALI models and intact lungs. All of them show 
that the longer liposomes circulate in the bloodstream, the 
more they accumulate in lungs (Wei et al. 2017).
A promising form of treatment for ALI is N-acetylcys-
teine (NAC). In isolated lungs and in vivo, it was shown 
that NAC reduces cell apoptosis of lung tissue (Chiang 
et al. 2012), while liposomal NAC had better pharma-
cokinetics and efficacy than free NAC, especially under 
systemic oxidative stress (Xu et al. 2012). Recently, there 
have been some studies on liposomal NAC in ALI, but 
only as an inhalant (Ourique et al. 2014), or as a means 
to prevent the development of ALI (Mitsopoulos et al. 
2008). There have been no experimental studies conside-
ring the therapeutic efficacy of liposomal NAC in aspira-
tion lung injury.
Recently, a number of studies have noted the effecacy 
of protease inhibitors such as aprotinin, ulinastatin when 
administered intravenously in relation to improving the 
morphological picture of lung tissue, oxygenation level, 
reducing pulmonary edema in ALI, but without descri-
bing their mechanism of action. Currently, there are some 
assumptions about possibility of using protease inhibitors 
in ALI treatment. They concern the reduction of leuko-
cyte infiltration of lung tissue, the level of interleukins 
and, accordingly, the pulmonary edema (Cao et al. 2018). 
The mechanism of therapeutic effect of aprotinin in ALI 
is associated with inhibition of proteolytic enzymes se-
creted by neutrophils (Li et al. 2015). Besides aprotinin, 
in rats with experimental acute pancreatitis, in addition 
to reducing the level of inflammatory mediators, also re-
duced the level of peroxynitrite and reactive oxygen spe-
cies and, like ulinastatin, reduced leukocyte infiltration of 
lung tissue and the degree of pulmonary edema (Cao et al. 
2018). Such data make it promising to study the use of the 
liposomal form of protease inhibitors for ALI treatment.
Due to the highly efficient loading of dexamethaso-
ne in liposomes, reaching 80–90% (Chen et al. 2013), 
liposomes with this drug are a very promising cure for 
ALI. Studies of the pharmacokinetics of liposomes with 
dexamethasone when administered intravenously showed 
a 5-fold higher accumulation of dexamethasone in lungs 
compared with a conventional solution of the same con-
centration (Chen et al. 2013). Recent studies confirm a 
more pronounced anti-inflammatory effect of liposomes 
with dexamethasone on lungs, due to a longer contact 
with the endothelium of pulmonary capillaries and the ac-
cumulation of a higher concentration the active substance 
in lungs (Li et al. 2018).
Biodistribution of liposomes in living objects can be 
investigated using optical imaging in the near infrared 
range, which eliminates absorption and scattering in bio-
logical tissues (Guan et al. 2017, Ravoori et al. 2016). The 
fluorescent dye Cyanine-7 (Cy-7) is suitable for such stu-
dies, because Cy-7 gets well anchored in liposome mem-
branes, because it has hydrophobic properties (Desu et al. 
2016). Cyanine dye is loaded into liposomes with quite 
high efficiency, up to 90% (Zou et al. 2013). If it is neces-
sary to investigate the biodistribution and accumulation 
of nanoparticles in internal organs, the use of Cy-7 as a 
fluorescent marker for liposomes is more preferable. This 
is primarily due not only to the emission wavelength, but 
also to the stability of the fluorescent signal after its admi-
nistration in vivo (Yu et al. 2012b). The near-infrared flu-
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orescent imaging is currently the most convenient way to 
monitor the dynamics of liposomal dosage forms in vivo 
because it is a non-invasive and non-ionizing method that 
allows for deep visualization of tissues, including lungs 
(Mizuno et al. 2009), and for investigation of the pharma-
cokinetics of drugs that are incorporated into nanocarri-
ers. With the help of preliminary calibration calculations, 
at present, the target properties of fluorescent liposomes 
can be quantified in relation to lungs tissue and the main 
pharmacokinetic indicators (Rajasekaran et al. 2015).
Materials and methods
Characteristics of hyperosmolar solutions
HyperHAES – solution for infusions produced by Frese-
nius Kabi Deutschland GmbH, Bad Homburg (Germany). 
The combination of 7.2% solution of NaCl and 6% HES 
with a molecular weight of 200000 Da and a degree of 
molar substitution of 0.5 (pentastarch) 60 g/L; pH 3.5–
6.0; osmolarity – 2464 mOsmol/L; Na 1232 mmol/L; Cl 
1232 mmol/L (Fominsky 2013).
7.5% NaCl solution, which was obtained in the chemi-
cal laboratory of Ogarev Mordovia State University from 
purified water and NaCl (c.p.), followed by autoclave ste-
rilization at a temperature of 120 °C and under pressure 
of 1 atm. Ingredients: Na 1283 mmol/L, Cl 1283 mmol/L; 
pH 4–6.0; osmolarity – 2566 mOsmol/L.
Production and analysis of liposomes
Liposomes were obtained by phase inversion from leci-
thin (phosphatidylcholine) EPCS 10 8018-1/130, Lipoid 
(Germany) and cholesterol Avanti Polar Lipids, Inc. 
(USA). To create liposomes, a Heidolph rotary evaporator 
was used (Germany). A dispersion of multilamellar vesi-
cles was passed through a polycarbonate filter with a pore 
diameter of 400 nm using an LIPEXTM extruder (Canada).
Purification of liposomal suspension from substances 
not included in liposomes was carried out using dialysis 
in an inert gas atmosphere under pressure of 0.3 MPa, as 
well with use of gel filtration, for which Sephadex G-75 
gel was used. Liposomes sizes were estimated using dyna-
mic light scattering on a NANO-flex analyzer (Microtrac 
Inc., USA). The amount of drug substance in liposomes 
was estimated by spectrophotometry using a Shimadzu 
spectrophotometer (Japan).
Cyanine-7 dye made by Biotech-Industry (Russia) was 
included in the lipid film before the formation of liposo-
mal vesicles and it was incorporated into liposome mem-
branes. The efficiency of dye incorporation into liposo-
mes was 98%, the concentration of Cy-7 in a liposomal 
suspension was 23 μg/ml, and the average diameter of 
liposomal vesicles was 313±2 nm.
When producing liposomal NAC (L-NAC), the li-
pid film was hydrated with 100 mg/ml of Fluimucil 
(N-acetylcysteine solution), (Zambon, Italy). Free NAC 
was separated from L-NAC through gel filtration. The 
amount of NAC incorporated into liposomes was deter-
mined spectrophotometrically by means of the reaction 
with FeCl3 and 1,10-phenanthroline at a wavelength of 
510 nm, using a previously constructed calibration cur-
ve. The degree of NAC inclusion into liposomes was 
12.5±2.5%. The average size of the obtained liposomes 
was 430±40 nm.
For obtaining liposomes with aprotinin, “Gordox” 
manufactured by Gedeon Richter Corp. (Hungary) was 
used, an injection solution, containing 10.000 KIU/ml 
of aprotinin. For the quantitative analysis of the obtained 
liposomes, a solution of Cy-7 with a concentration of 27 
μg/ml was used. Cy-7 served as an optical marker of apro-
tinin molecules in the quantitative analysis of liposomes. 
Liposomes were purified from free dye and the dye which 
had failed to bind to aprotinin by means of dialysis me-
thod. According to the results of spectrophotometry (λ = 
760 nm), 252.156 μg of Cy-7 dye binds to 120.000 KIU of 
aprotinin, the binding efficiency was 77.8%. Purification 
of liposomes from the free complex aprotinin-Cy-7 was 
carried out by gel filtration. The results of the quantita-
tive analysis of liposomes with aprotinin showed a 3184.8 
KIU/ml concentration of the drug in liposomal suspen-
sion, with entrapment efficiency of 31.85%. Liposomes 
containing aprotinin were of 312.3±12.5 nm in size.
For producing liposomes, “Dexametsone” was used 
solution for injection 4mg/ml, KRKA Novo mesto, Slove-
nia. Lipid film dried on a rotary evaporator was hydrated 
with a hypertonic solution of sodium chloride (75 mg/ml), 
containing dexamethasone at a concentration of 4 mg/ml. 
Purification of liposomes from free dexamethasone was 
performed through dialysis. Quantitative determination of 
dexamethasone content in liposomes was made by means 
of spectrophotometry at λ=241 nm. The average diameter 
of liposomes was 320±50 nm. The concentration of dexa-
methasone in the purified liposome dispersion was 2.9795 
mg/ml±0.015 mg/ml. The drug entrapment efficiency in 
liposomes was 74.5%±0.4%.
Modeling acute lung injury and anesthesia
In the experiment, two models of ALI were used. The 
first model involved injection of acetone in an amount of 
0.1 mg/kg into the trachea (Kulikov et al. 2015), the se-
cond model involved intratracheal administration of aci-
din-pepsin solution (1 tablet per 0.5 ml of normal saline) 
in the amount 0.03 ml per one animal. For the experiment, 
white non-linear rats of both sexes weighing 220–300 g 
were used from Stolbovaya nursery (Research Center 
for Biomedical Technologies of the Russian Academy of 
Medical Sciences). For the experiment,“Acidin-Pepsin” 
tablets containing 200 mg of betaine hydrochloride and 
50 mg of pepsin were used, (Belmedpreparaty, Republic 
of Belarus) (Moroz et al. 2010). The procedure for ALI 
modeling was an operation during which an incision of 
about 5 mm in size was made in the rat’s neck area to get 
access to the trachea, above the thyroid gland, and then a 
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18G catheter was inserted into the trachea. The catheter 
was filled with the appropriate agents, then they were ad-
ministered into the trachea, after which the catheter was 
removed and the incision was sutured. To prevent reflex 
respiratory arrest, artificial lung ventilation was used, 
with the parameters of 500 ml/min, respiratory rate (RR) 
of 60 per minute, and respiratory volume of 5 ml/kg of 
animal weight. The surgical manipulations with animals, 
including euthanasia, were performed under injection an-
esthesia (8 mg/kg of Rometar and 20 mg/kg of Zoletil 
intravenously into the lateral vein of the tail). The experi-
ment was carried out after the approval by the local ethics 
committee in accordance with the rules for working with 
laboratory animals formulated in Directive 2010/63/ EU 
of the European Parliament and the Council of the Euro-
pean Union on the Protection of Animals Used for Scien-
tific Purposes (Directive 2010).
Experimental protocol
After ALI modeling, all the animals were injected with 
ceftriaxone (bottled powder, 1g. for preparing a solution 
for intramuscular and intravenous administration, Bio-
sintez, Russia) at a dose of 200 mg/kg, intramuscularly 
once a day for 6 days (for basic support in ALI) (Galvão 
et. al. 2016). For the two models of ALI, 5 groups of 
animals were formed. The animals of Group 1 (control 
1) received no other treatment. The animals of the expe-
rimental groups received the therapy, which consisted of 
a single intravenous administration of the test agents 20 
minutes after intratracheal administration of the dama-
ging agent. The rats in Group 2 (control 2) were injec-
ted with dexamethasone at a dose of 6 mg/kg. In Group 
3, the animals were intravenously injected with 75mg/
ml (7.5%) hypertonic solution of sodium chloride. In 
Group 4, the animals were intravenously administered 
HyperHAES solution as a single dose. Hypertonic solu-
tions were administered at a dose of 4 ml/kg (Fominsky 
2013). In Group 5, during acetone aspiration, the ani-
mals were injected intravenously with 0.5 ml of liposo-
mal suspension with N-acetylcysteine (NAC average 
dose of 25–30 mg/kg), and in acidin-pepsin aspiration, 
liposomal aprotinin (L-aprotinin) was injected intraven-
ously at a dose of 12.000 KIU/kg. A separate group con-
sisted of intact rats.
Therapeutic efficacy of liposomal form of dexame-
thasone in hyperosmolar aqueous medium HLD was in-
vestigated on ALI model, using acidin-pepsin. The ani-
mals were once intravenously injected with 0.5–0.6 ml 
hyperosmolar liposomes at a dexamethasone dose of 6 
mg/kg, 5 minutes after the pathology modeling. Treat-
ment efficacy was compared with that in case of intraven-
ous administration of a dexamethasone solution at a dose 
of 6 mg/kg in combination with hypertonic (7.5%) sodi-
um chloride solution (HS+Dex). The dose of hypertonic 
saline with intravenous administration of liposomes with 
and in the comparison therapy was 2 ml/kg.
Evaluating the efficacy of the ALI 
experimental therapy
Functional indicators
Registration of physiological parameters was carried out 
by means of Biopac MP 150 (BIOPAC Systems, Inc., 
USA). The animals were evaluated in teems of their exter-
nal respiration parameters: hemoglobin saturation (SpO2), 
respiratory rate (RR); indicators of the cardiovascular 
system: the heart rate (HR); blood pressure (BP): systolic 
and diastolic. The pressure was measured noninvasively 
on the tail. The functional indicators in all experimental 
groups were recorded at 60 min, 24 hours and 6 hours 
after the modeling of ALI. In the study of the therapeutic 
efficacy of liposomal dexamethasone, the physiological 
parameters were recorded 20 minutes before the ALI mo-
deling, 5 minutes afterwards and then further 5, 30, 60, 
120, 240 minutes, 24 hours and 6 days after the time of 
applying the treatment.
Calculation of survival
To assess the effectiveness of the compared therapy me-
thods, mortality was recorded within 6 days from the mo-
ment of ALI modeling, the percentage of surviving ani-
mals (survival rate) was determined by the formula (XS/
XC)/100%, where XS is the number of animals surviving 
on the 6th day of the experiment, XC – the number of ani-
mals in the group.
Analysis of the degree of pulmonary edema
For the experiment, similar experimental groups were for-
med, each containing 10 animals. Part of the animals were 
sacrificed on the first day, whereas the others – on the 6th 
day after the start of the experiment under anesthesia by 
careful simultaneous sectioning carotid arteries without 
traumatizing the trachea (Gushchin and Muzhikyan 
2014). In the animals, the lungs were removed and weig-
hed, followed by determining the degree of pulmonary 
edema – Lung-body (LB) ratio. LB ratio was calculated 
by the formula: weight of lungs/weight of animal×1000 = 
units (Torkunov 2007).
In vivo imaging biodistribution of 
liposomes
For calibrating the method, in advance the curve showing 
the dependence of concentration of liposomal and free 
dye Cy-7 on fluorescence intensity was constructed. For 
this purpose, various dilutions of Cy-7 dye had been pre-
pared.
The study was carried out on white outbred male mice 
weighing 20–23 g. Liposomes with fluorescent dye Cy-7 
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were intravenously administered in the lateral tail vein in 
a volume of 0.2 ml per animal. The animals were sacri-
ficed by decapitation under general anesthesia 2.5, 5, 10, 
15, 20, 30, 40 and 60 min after intravenous administra-
tion. The internal organs (liver, lungs and kidneys) were 
removed and weighed; also 0.2 ml of blood was taken. 
The organs and blood were placed in IVIS Lumina II ap-
paratus (Caliper, USA), and fluorescence intensity was 
recorded. Fluorescence intensity was converted to the 
number of micrograms of the dye per 1 gram of organ tis-
sue. The conversion was carried out according to the ca-
libration curve and taking into account the density of the 
target organ tissue. Density of the organs was calculated 
experimentally in 10 individual mice of the same weight 
– 22 g. The number of the animals for each time point in 
both series of was experiments was n=5.
Statistical analysis
The observed differences in numerical values were evalu-
ated using Student’s t-test and χ-square test. A conclusion 
about statistically significant differences was made with a 
significance level (p) <0.05.
Results
Twenty-four hours after acetone aspiration, 61.53% of the 
animals which had been administered only with an anti-
biotic died. Mortality in the group of animals treated with 
dexamethasone was 30% (Fig. 1). Mortality in the groups 
with a single administration of hypertonic saline and Hy-
perHAES solution was 41.6% and 25%, respectively, 
which, in case of administering HyperHAES, was signi-
ficantly less than that in the group without experimental 
treatment. Mortality in rats that had received a single dose 
of liposomal NAC was 14.3%, which was significantly 
lower than that in the control, where only one antibiotic 
had been used. On the 2nd day of observation, the num-
ber of deaths in all experimental groups increased. In the 
control group, mortality was 76.9%, in the group of dexa-
methasone – 40%, and after administration of hyperto-
nic saline solution and HyperHAES – 47.1% and 37.5%, 
respectively (Fig. 1). On the 2nd day after application of 
liposomal NAC, 21.4% of rats died. The values reflecting 
mortality rates in the groups where the treatment had been 
carried out, except for the group with hypertonic sodium 
chloride, were significantly lower than that in the group 
where experimental therapy had not been carried out. 
On the 3rd day, all the animals in the control group died 
(Fig. 1). The 3rd day also saw a mortality rate in the group 
after application of liposomal NAC increasing to 28.6%. 
The mortality rate was less than that in the control group 
without experimental treatment.
Saturation of blood hemoglobin (SpO2) in the animals 1 
hour after acetone aspiration reduced from 95.76±0.63% 
in the normal condition to 78.4±1.67% in the control 
group (Fig. 2). Under the influence of experimental the-
rapy and comparing therapy with dexamethasone, the sa-
turation was higher in when compared to the group, in 
which only support antibiotic therapy had been used. In 
the dexamethasone group, the hemoglobin saturation was 
86.8±2.2% one hour later. The highest saturation was in 
a group with HS 87.7±1.3%, with a solution HyperHAES 
– 85.8±2.0%. L-NAC supported hemoglobin saturation 
level – 85.7±1.3%.
One day after aspiration of acetone in the control 
group, the level of SpO2 was 86.0±5.3% (Fig. 3). The 
support of a sufficiently high level of oxygenation was 
provided with hyperosmolar solutions and dexamethaso-
ne. After administration of dexamethasone, the level of 
SpO2 was 94.0±1.34%. After administration of HS and 
HyperHAES, the levels of SpO2 were 93.7±3.2% and 
90.7±2.3%, respectively: At the same time, L-NAC was 
inferior to dexamethasone in efficacy at the saturation le-
vel of 88.3±1.91% (Fig. 3).
The figure shows that on the 6th day, there was no 
difference between the levels of SpO2 in experimental 
therapy with hyperosmolar solutions and in the treatment 
of L-NAC, the levels remaining reduced relative to the 
norm (Fig. 4). Hemoglobin saturation levels in groups 
with dexamethasone and L-NAC were 85.8±1.3% and 
88.0±2.5%, respectively, and in groups with HS and 
Figure 1. Animal survival in acute lung injury caused by aspiration of acetone after using various types of therapy.
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HyperHAES– 89.0±1.2% and 86.0±5.3%. In the group 
with L-NAC, the SpO2 level tended to increase, whereas 
in the others – to decrease (Fig. 4).
In the intact animals, RR was 83.1±6.1 breaths per 
minute (1/m). This indicator shows that L-NAC to-
gether with HS and HyperHAES kept RR at the level 
corresponding to that of the intact animals – about 80–
90/min (Table 1) 1 hour after their application. Twen-
ty-four hours later, the respiration rate in the group 
where the dexamethasone was used remained 27.7% 
higher than that in the intact animals and 44.9% higher 
than that in the group where HS had been administered 
(Table 1).
RR on the 6th day of the experiment in the group of 
animals, where HyperHAES solution had been used, was 
28.9% lower than that in the group after the administrati-
on of dexamethasone. In the group after administration of 
liposomal NAC, RR in rats was significantly lower than 
that in the group of animals treated with dexamethasone 
– by 23.4% (Table 1).
Figure 2. The changes of blood hemoglobin saturation in rats 1 hour after administration of the studied agents on the background 
of acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals; p2 – in relation to 
control group 1 (0.1 ml/kg of acetone intratracheally).
Figure 3. The changes in blood hemoglobin saturation levels in rats 24 hours after administration of the studied agents on the back-
ground of acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals. p3 –in relation 
to the control group 2 (dexamethasone 6 mg/kg, intravenously, once + ceftriaxone 200 mg/kg).
Figure 4. The changes in blood hemoglobin saturation levels in rats 6 days after administration of the studied agents on the back-
ground of acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals.
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HR of healthy rats with appropriate anesthesia was 
353.7±19.4 beats per minute (1/min). The intravenous 
administration of L-NAC clearly affected the heart rate 
1 hour after administration. The heart rate increased to 
334.0±15.0/min. At the same time, the heart rate remain-
ed low in other types of therapy, which makes it impos-
sible to talk about correcting this indicator with dexame-
thasone and hypertonic solutions in this model (Table 1).
In the intact rats, blood pressure was 136.7±6.0/97.7±4.9 
mm Hg. None of the therapeutic regimens showed any hy-
pertensive effect 1 hour after the time the aspiration aceto-
ne, which was not typical of drugs, such as dexamethasone 
and hypertonic solutions based on sodium chloride. At the 
same time, L-NAC caused no increase in blood pressure 
to reach the level of the intact animals (Table 1). However, 
systolic and diastolic BP levels 1 hour after administration 
of L-NAC were significantly higher than the levels of BP 
after acetone aspiration without the experimental therapy.
Maintaining a higher blood pressure after the adminis-
tration of L-NAC compared to that when using Hyper-
HAES solution is an interesting fact, possibly related to 
the effect of the liposomes, which requires further special 
investigation.
Twenty-four hours after administration, there was 
no hypertensive effect in the group of L-NAC, which is 
consistent with the fact that this drug has no hypertensi-
ve effect. On the contrary, the agents having undeniable 
hypertensive properties, such as HS, dexamethasone and 
HyperHAES, maintain blood pressure at the level close 
to the normal levels 24 hours after administration. The 
action time can be assumed by the effect on the blood 
pressure level. At the end of the experiment on the 6th day, 
low blood pressure was observed in the groups in which 
hyperosmolar solutions, dexamethasone and L-NAC had 
been used (Table 1). These differences can not be explain-
ed by using the data available in the study.
The ALI model induced by administration of aci-
din-pepsin into the trachea along with the supporting the-
rapy by means of ceftriaxone resulted in 50% of deaths in 
the group. Using the above treatment regimens, including 
using liposomal aprotinin, failed to significantly change 
the mortality rate within 6 days of the experiment. The 
highest rate of the animals’ survival was observed in 
the group with a conventional HS. On the 6th day, it was 
83.3%. On 1st day, it was significantly higher than that 
without the experimental treatment and reached 91.7%. 
Table 1. Changes in functional indicators in rats, with acute lung injury caused by aspiration of acetone after administration of the 
compared means of therapy (M±m, n=10).
Time Indicators Groups of experimental therapy
Control Dexametasone HS HyperHAES L-NAC
1 hour RR 1/min 56.5±7.6 
р1<0.05
106.1±6.8 
р1,2<0.05
80.6±7.4 
р2,3<0.05
89.0±6.3 
р2<0.05
98.0±7.9 
р2<0.05
HR 1/min 284.2±24.8 
р1<0.05
268.4±23.7 
р1<0.05
262.0±17.2 
р1<0.05
303.8±10.6 
р1,4<0.05
334.4±14.6 
р3,4<0.05
Systolic BP mm Hg. 72.0±13.0 
р1<0.05
87.6±9.6 
р1<0.05
89.7±5.3 
р1<0.05
95.4±5.6 
р1<0.05
105.1±5.1 
р1,2<0.05
Diastolic BP mm Hg 39.1±8.4 
р1<0.05
55.4±7.2 
р1<0.05
58.5±4.4 
р1<0.05
61.8±4.1 
р1,2<0.05
73.9±5.2 
р1,2,4<0.05
24 hours RR 1/min 86.3±6.0 106.1±9.5 
р1<0.05
73.2±6.7 
р3<0.05
79.7±2.9 82.0±12.8
HR 1/min 400.2±22.1 323±18.1 
р2<0.05
312.3±17.1 
р2<0.05
392±19.0 
р4<0.05
363.3±19.2
Systolic BP mm Hg 93.0±27.0 
р1<0.05
127.4±8.1 115.7±15.4 133.0±20.0 102.3±11.0 
р1<0.05
Diastolic BP mm Hg 70.5±20.6 92.6±6.7 80.0±13.0 95.0±8.0 74.6±10.2 
р1<0.05
6 days RR 1/min – 101.0±6.5 90.7±16.6 71.8±13.0 
р3<0.05
77.3±7.1 
р3<0.05
HR 1/min – 396.8±20.5 402.8±16.0 347.4±25.7 357±18.2
Systolic BP mm Hg – 133.0±10.9 107.6±10.1 
р1<0.05
101.6±16.9 
р1<0.05
144.3±20.8
Diastolic BP mm Hg – 98.3±6.9 65.4±7.3 
р1,3<0.05
65.8±15.8 
р1<0.05
116.0±16.9 
р4<0.05
Note: p1 – significance of differences, calculated in relation to the group of intact animals.p2 –in relation to control group 1 (acetone 
intratracheally 0.1 ml/kg); p3 –in relation to control group 2 (dexamethasone 6 mg/kg, intravenously, once + ceftriaxone 200 mg/
kg); p4 - in relation to the group treated with hypertonic saline intravenously once 4 ml/kg + ceftriaxone 200 mg/kg; HS – hypertonic 
saline; L-NAC – liposomal NAC; RR – respiratory rate; HR – heart rate; BP – blood pressure.
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The animals which had received dexamethasone had a 
survival rate of 60%, those animals which had received 
liposomal aprotinin – 73.4% (Fig. 5). On the 1st day after 
administration of HyperHAES solution, the survival rate 
among the animals reached 75%, on the 2nd day – 62.5%.
One hour after the application, the therapy by means 
of HS, HyperHAES and liposomal aprotinin increased 
the SpO2 level relative to the reference therapy based on 
a single administration of dexamethasone (Fig. 6). The 
survival rate and the SpO2 level were the highest with the 
administration of HS – 85.3±1.9% – on the first day of 
the experiment. In other groups, an increase in hemoglo-
bin saturation was also accompanied with an increase in 
the survival rate. After administration of dexamethasone, 
the SpO2 level was the lowest among the reference regi-
mens and reached 78.8±1.5%. When using HyperHAES, 
hemoglobin saturation reached 83.0±0.9%, when using 
liposomal aprotinin – 84.5±0.5%. Lack of significant dif-
ferences from control group 1 makes it impossible to talk 
about the effectiveness of experimental therapy one hour 
after the application (Fig. 6).
Twenty-four hours later, the situation changed. Liposo-
mal aprotinin kept the SpO2 level at the same level as that 
one hour after administration – 83.5±2.1% (Fig. 7). In the 
groups of animals with administration of hyperosmolar 
solutions, by that time hemoglobin saturation was the 
lowest (Fig. 7). After administration of HS and Hyper-
HAES, the SpO2 level was 78.3±2.6% and 78.6±0.9%, 
respectively. The rats which had received dexamethaso-
ne retained a higher level of SpO2 – 83.2±1.2%. The 
recovery of the SpO2 level in the control group reached 
82.4±2.3%. Changes in oxygenation on the 1st day after 
applying the therapy reflect the causes of the survival pat-
tern formation of the experimental animals at the same 
time (Fig. 7).
In the group where for the animals were given an an-
tibiotic for 6 days, the SpO2 level was 86.7±2.2%, in the 
group of dexamethasone – 82.6±2.1%. The rats that had 
received HS and HyperHAES as a treatment of on the 6th 
day had the SpO2 level of 83.7±4.0% and 81.2±2.0%, res-
pectively. Rats that had received liposomal aprotinin had 
saturation of 85.0±1.2% on the 6th day. For all the types 
of therapy, the SpO2 level on the 6th days it was lower than 
that in healthy rats (Fig. 8).
One hour after aspiration of acidin-pepsin and intra-
venous administration of HS, the respiratory rate was 
28.9% higher than that in the intact animals and 35.8% 
higher than that in control group 1 (Table 2). Twenty-four 
hours later, RR in the control group was high relative to 
the healthy animals and exceeded that by 24.8%. In the 
group with the administration of HS, 24 hours later the 
RR was also high, exceeding that in the intact animals 
Figure 5. Animal survival rate in acute lung injury caused by aspiration of acidin-pepsin after using various types of therapy.
Figure 6. The changes in blood hemoglobin saturation in rats 1 hour after administration of the studied agents on the background 
of acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals. p3 – in relation to 
control group 2 (dexamethasone 6 mg/kg, intravenously once+ ceftriaxone 200 mg/kg).
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by 41.6%. Six days after the aspiration lung injury, the 
respiratory rate was high in the groups where the ani-
mals had received hypertonic solutions. In particular, 
6 days after the administration of HS, RR was 34.8% 
higher than that in the healthy rats, and, in the group with 
the administration of HyperHAES, RR exceeded such in 
the group of the intact animals by 51.3%, in the control 
group – by 52.5 % and in the group with dexamethasone 
– by 84.8% (Table 2).
The role of dysfunction of the cardiovascular system in 
the general status and mortality of the experimental ani-
mals with acute lung injury induced by acidin-pepsin can 
be traced at an early stage, 1 hour after the application of 
the therapy. Thus, it is possible to observe reduction in the 
heart rate by 15%. Against this background, hypotension 
developed, systolic BP reduced by 31%, diastolic – by 
31%. The hyperosmolar solutions and liposomal aprotinin 
used stabilize, in the first place, the heart rate (Table 2). The 
stimulating effect of hyperosmolar solutions on the level 
of systolic BP was also registered one hour after applicati-
on of the therapy. In the same case, the reference therapy, 
which included the administration of dexamethasone, as 
well as the administration of liposomal aprotinin, had no 
corrective effect on the level of blood pressure (Table 2).
Twenty-four hours and then 6 days later, no significant 
changes in either heart rate or blood pressure were recor-
ded, which would correspond to changes in the mortality 
rate in the studied groups. Thus, the recovery of the func-
tion of the cardiovascular system in surviving rats hap-
pened in a similar manner as in the previous model, with 
the use of acetone, which is due to a one-time therapy 
application (Table 2).
The experiment with fluorescent liposomes in mice 
with eviscerating the internal organs showed the follo-
wing; Up to the 20th minute from the moment of intra-
venous injection, the liposomal and free dyes had a quite 
close concentration in blood, within the statistical error 
(Fig. 10). At the same time, the concentration of free dye 
in the lungs was 0.36±0.04 µg/g of tissue, liposomal dye 
– 0.69±0.06 µg/g, which was twice as much, and this was 
the largest difference in the accumulation of liposomal 
Cy-7 in lung tissue between the groups.
In the lungs and in blood, the concentration of the flu-
orescent dye, administered as a solution, did not change 
significantly until the 60th minute of observation (Fig. 9). 
At the same time, accumulation of the dye began in the 
liver staring with the 20th minute and lasted until the 60th 
minute, when it reached a maximum of 2.43±0.25 μg/g 
Figure 7. The changes in blood hemoglobin saturation in rats 24 hours after administration of the studied agents on the background 
of acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals. p3 – in relation to 
control group 2 (dexamethasone 6 mg/kg, intravenously once + ceftriaxone 200 mg/kg). р
5
 – in relation to the group with Hyper-
HAES 4 ml/kg intravenously once + ceftriaxone 200 mg/kg.
Figure 8. The changes in blood hemoglobin saturation in rats 6 days after administration of the studied agents on the background of 
acute lung injury. Note: p1 – significance of differences, calculated in relation to the group of intact animals.
Kulikov OA et al.: Efficacy of  liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy32
of tissue (Fig. 11). A different process took place with 
liposomal Cy-7. Starting with the 20th minute, a decrease 
in the concentration of liposomal dye in the blood and 
lungs began, and a decrease in the Cy-7 content in the li-
ver stopped. The concentration of the dissolved dye in the 
lungs at the point of the 20th minute was 1.8 times higher 
than that in the blood. In the case of liposomes, the same 
concentration at the point of the 20th minute was 4 times 
higher in lung tissue. This may clearly indicate a more 
intense accumulation of liposomes in the lungs compared 
with the usual solution of the substance.
At the 40th minute, the concentrations of dissolved and 
liposomal Cy-7 in the lungs were comparable (Fig. 9). In 
the lungs 40 minutes later, the concentration of the liposo-
mal dye was 8.3 times higher than that in blood, while for 
the solution this difference was 1.75 (Fig. 10). Then, at 
the 60th minute, the concentration of liposomal Cy-7 was 
6.5 times higher than that in blood at the same time, and 
for the solution, the Cy-7 concentration ratio in blood and 
lungs remained the same. Starting with the 40th minute, 
there began an intensive accumulation of liposomal Cy-7 
in the liver to reach 1.63±0.2 μg/g of tissue, which was 
Table 2. Changes in functional indicators in rats with acute lung injury caused by aspiration of acidin-pepsin after administration of 
reference therapeutic drugs (M±m, n=10).
Time Indicators Groups of experimental therapy
Control Dexametasone HS HyperHAES L-aprotinin
1 hour RR 1/min 78.8±7.9 80.0±8.7 106.9±8.5 
р1,2<0.05
75.7±6.1 р4<0.05 97.4±4.5 
р
5
<0.05
HR 1/min 298.4±16.4 
р1<0.05
313.7±23.1 310.1± 25.1 380.5±17.8 
р2,3,4<0.05
325±15.3 
р
5
<0.05
Systolic BP mm Hg. 93.5±6.5 
р1<0.05
103.4±13.1 
р1<0.05
124.1±11.6 
р2<0.05
121.3±9.8 
р2<0.05
108.0±4.6 
р1<0.05
Diastolic BP mm Hg 67.5±6.8 
р1<0.05
72.3±11.3 
р1<0.05
77.0±8.0 
р1<0.05
87.2±9.9 80.3±4.8 
р1<0.05
24 hours RR 1/min 103.7±6.5 
р1<0.05
97.0±15.9 117.7±4.4 
р1<0.05
102.5±22.5 112.5±18.5
HR 1/min 364.3±19.8 328.0±24.0 369.0±19.1 347.5±39.5 294.6±22.7
Systolic BP mm Hg. 122.9±6.1 146.7±19.1 149.0±8.5 111.5±6.5 111.5±12.6
Diastolic BP mm Hg 91.6±5.0 96.0±17.2 105.3±13.3 87.8±20.2 75.5±15.1
6 days RR 1/min 82.4±7.4 68.0±14.7 112.0±13.6 
р1<0.05
125.7±12.7 
р1,2,3<0.05
82.2±11.4
HR 1/min 329.6±21.3 328.7±77.2 404.8±14.9 
р2<0.05
411.3±33.3 401.8±10.3 
р2<0.05
Systolic BP mm Hg. 132.0±11.2 144.7±5.9 107.4±17.8 136.0±9.1 132.0±13.0
Diastolic BP mm Hg 102.6±9.5 102.0±6.8 63.2±15.7 
р1,2<0.05
97.7±7.3 94.8±9.8
Note: p1 – significance of differences, calculated in relation to the group of intact animals; p2 – in relation to control group 1 (aci-
din-pepsin intratracheally 0.1 ml/kg); p3 – in relation to control group 2 (dexamethasone 6 mg/kg, intravenously once + ceftriaxone 
200 mg/kg); p4 – in relation to the group with hypertonic saline intravenously once at a dose of 4 ml/kg + ceftriaxone 200 mg/kg; 
р
5
 – in relation to the group with HyperHAES once at a dose of 4 ml/kg + ceftriaxone 200 mg/kg; HS – hypertonic saline; RR – re-
spiratory rate; HR – heart rate; BP – blood pressure.
Figure 9. Accumulation dynamics of liposomal and dissolved dye Cyanine-7 in the lung tissue of mice after intravenous administration.
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less than that for the dissolved form of the dye at the same 
time point (Fig. 9).
The dynamic pattern of the Cy-7 dye concentration in 
kidney tissue can be accounted for the similar processes. 
Liposomes accumulate in renal glomeruli (Kraft et al. 
2014). The result is that within the first 30 minutes the 
concentration of the dye exceeded thee liposomal dissol-
ved dye concentration. A slow increase in the concentra-
tion of free and liposomal dyes in kidneys from the 40th 
to the 60th minutes after intravenous administration may 
be associated with the elimination of Cy-7 released from 
liposomes (Fig. 12).
Hyperosmolar liposomes with dexamethasone HLD 
compared with a combined therapy comprising HS and 
dexamethasone promoted a higher survival rate of animals 
with ALI caused by aspiration of acidin-pepsin. The sur-
vival rate after 6 days of the experiment in the group with 
HLD was 86.7%, in the group with HS+Dex – 66.7%, 
despite the fact that the similar doses of dexamethasone 
and HS were received by the animals in both groups. In 
comparison with the animals exposed to ALI induced by 
acidin-pepsin and treated with ceftriaxone, only HLD ad-
ministration showed a statistically significant increase in 
the survival rate.
Looking at the dynamics of the therapeutic effect of 
HLD, the largest differences between the experimental 
and control groups were observed 4 hours after intraven-
ous administration of the therapeutic agents. Until then, 
in both groups the SpO2 level had been recovering with 
equal intensity. Five minutes after aspiration, the saturati-
on in the group treated with HLD decreased to 79.4±3.7%, 
while in the control group – to 76.9±3.4% (Fig. 13). At the 
point of the 2nd hour after the intravenous injection, satu-
ration in the groups with HLD was 89.6±1.4%, in control 
– 89.0±1.4%. But by the 4th hour, in the group with HLD, 
the SpO2 level increased, reaching 92.6±1.0%, while in 
the control it decreased to 86.5±1.7%. The opposite trend 
with the SpO2 changes may be due to the fact that liposo-
mal and free dosage forms of dexamethasone were used 
in the experiment. The liposomal form continued to cor-
rect respiratory disorders, while HS+Dex 4 hours later did 
not contribute to the growth of hemoglobin saturation. In 
the experimental group with HLD and in the group with 
HS+Dex, one day after administration, the saturation le-
vels were 90 and 89%, respectively (Fig. 13).
A more prolonged positive effect of HLD on the res-
piratory function was confirmed by the various dynamics 
of the respiratory rate. In the group with HLD, during the 
development of ALI, the respiratory rate was suppressed 
from 85.3±7.0/min to 74.6±14.8/min. In the group with 
HS+Dex therapy, a decrease was more significant – from 
65.4±6.3/min to 44.0±6.9/min (Fig. 14). But only in the 
latter case, it was possible to speak about the reliable 
oppression of RR. The graph of the change in RR shows 
Figure 10. Accumulation dynamics of liposomal and dissolved dye Cyanine-7 in the blood of mice after intravenous administration.
Figure 11. Accumulation dynamics of liposomal and dissolved dye Cyanine-7 in the liver tissue of mice after intravenous administration.
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that at the 4th hour in the HLD group there was a ten-
dency for an increase in RR, i.e. recovery to the initi-
al value, whereas in the group with the combination of 
HS+Dex there was a reverse trend, i.e. a decrease in RR, 
with a return to the value 5 minutes after aspiration of 
acidin-pepsin (Fig. 14).
Twenty-four hours later, the RR was restored to the 
baseline in both groups. Also it can be assumed that the 
combination of HS+Dex had a faster, but less prolonged 
stimulatory effect on the respiratory function. HLD led 
to an increase in RR by 30 minutes at a delayed point 
in time (Fig. 14). The therapeutic effects of HLD and 
HS+Dex when analysing the inspiratory and expiratory 
rates, as well as the expiratory volume, are similar. In 
both groups, there was a similar positive dynamics in 
the recovery of inspiratory rate, expiratory expiratory 
rate and expiratory volume. There was no difference in 
the speed of an onset of the effect with respect to the-
se indicators. An important difference was the different 
levels of SpO2 in the control and experimental group 
on the 6th day of observation. In the group with HLD, 
the SpO2 level was 88.6±1.3%, which was significantly 
higher than that 5 minutes after aspiration prior to ad-
ministration of the therapeutic agent. In the group with 
treatment with HS+Dex, after 6 days the SpO2 level was 
86.0±2.0% and had no statistically significant differen-
ces from the SpO2 level which was fixed 5 minutes after 
aspiration of acidin-pepsin. These data may indicate a 
significant disruption of the respiratory function in the 
group treated with the reference therapy and, therefore, 
its lower effectiveness.
Functional diagnostics of the cardiovascular system 
demonstrated the effectiveness of HLD compared to the 
therapy with HS+Dex. HLD corrected the heart rate in a 
more pronounced way. As a result of aspiration, the heart 
rate was depressed. The heart rate in both groups reduced 
on average by 50% of the original (Fig. 15). In the healthy 
animals before aspiration of acidin-pepsin the heart rate 
was about 215/min for both groups of animals. After as-
piration, administering HLD caused 30 minutes later an 
increase in the heart rate from 123±16/min to 193±16/
min (Fig. 15). Further growth continued, and an hour later 
Figure 12. Accumulation dynamics of liposomal and dissolved dye Cyanine-7 in kidney tissue of mice after intravenous administration.
Figure 13. Hemoglobin saturation in rats with acute lung injury after using hyperosmolar liposomal dexamethasone (1) and dexa-
methasone in combination with hypertonic saline (2). Note: # – significance of differences calculated in relation to the value 5 
minutes after the simulation of acute lung injury, at p<0.05; * – significance of differences calculated between the control and exper-
imental groups, at p<0.05; + – significance of differences calculated in relation to the initial value, at p<0.05.
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the heart rate was 221.9±18.8/min. Two, four and twen-
ty-four hours after administration of HLD, the heart rates 
were 216±19.5, 248.8±19.8 and 233.9±13.2/min, respec-
tively.
In the control group 30 minutes later, the heart 
rate, though had increased from 142.5±10.4/min to 
168.2±16.3/min, remained significantly lower than the 
initial value. In the control group 1 hour, 2 and 4 hours 
later, the heart rates in rats were 180.2±16.2, 189.7±20.5 
and 176.9±18.0/min, respectively (Fig. 15). At those time 
points, the heart rate was not significantly higher than that 
5 minutes after aspiration of acidin-pepsin.
The effect of HLD therapy and HS+Dex therapy on 
systolic blood pressure was similar (Fig. 16).
One may notice the different pattern of the dynamics of 
diastolic BP 4 hours after the intravenous administration 
of the therapeutic agents. While in the experimental group 
of rats with HLD, diastolic BP continued to grow to reach 
119.7±6.3 mm Hg, in the control group, it decreased to 
97.1±7.1 mm Hg (Fig. 17). In this case, again one can assu-
me a longer effect of HLD compared with that of HS+Dex.
HyperHAES and HS affected the degree of pulmonary 
edema in different ways. On the first day, HyperHAES 
was more effective, as it reduced the level of pulmonary 
edema compared to the animals without administration of 
the experimental therapeutic agents (Table 3). A similar ef-
fect was observed after administration of dexamethasone 
(control 2). HS did not affect significantly on the LB ratio.
On the 6th day after the administration of hyperosmolar 
solutions, it was possible to compare the LB ratio only 
with that in the intact animals. After treatment with HS 
and HyperHAES solution and the reference treatment 
Figure 14. Respiratory rate in rats with acute lung injury after using hyperosmolar liposomal dexamethasone (1) and dexamethasone 
in combination with hypertonic saline (2). Note: # – significance of differences calculated in relation to the value 5 minutes after the 
simulation of acute lung injury at p<0.05; * – significance of differences is calculated between the control and experimental groups 
at p<0.05; + – significance of differences calculated in relation to the initial value at p<0.05.
Figure 15. Heart rate in rats with acute lung injury after using hyperosmolar liposomal dexamethasone (1) and dexamethasone in 
combination with hypertonic saline (2). Note: # – significance of differences calculated in relation to the value 5 minutes after the 
simulation of acute lung injury at p<0.05; * – significance of differences calculated between the control and experimental groups at 
p<0.05; + – significance of differences calculated in relation to the initial value at p<0.05.
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Figure 16. Systolic blood pressure in rats with acute lung injury after using hyperosmolar liposomal dexamethasone (1) and dexa-
methasone in combination with hypertonic saline (2). Note: # – significance of differences calculated in relation to the value 5 
minutes after the simulation of acute lung injury at p<0.05; * – significance of differences calculated between the control and exper-
imental groups at p<0.05; + – significance of differences calculated in relation to the initial value at p<0.05.
Figure 17. Diastolic blood pressure in rats with acute lung injury after using hyperosmolar liposomal dexamethasone (1) and 
dexamethasone in combination with hypertonic saline (2). Note: # – significance of differences calculated in relation to the value 5 
minutes after the simulation of acute lung injury at p<0.05; * – significance of differences calculated between the control and exper-
imental groups at p<0.05; + – significance of differences calculated in relation to the initial value at p<0.05.
with dexamethasone , an increase in pulmonary edema 
was observed by the 6th day of the experiment. The LB ra-
tio was significantly higher than that in the intact animals 
(Table 3). Thus, it is difficult to talk about the advantage 
of any one hyperosmolar solution for infusions, as the 
most effective one for eliminating pulmonary edema in 
this model. HyperHAES and HS had no antiedematous ef-
fect during aspiration of acetone by the experimental ani-
mals. Compared with other experimental groups L-NAC 
was the best in preventing the development of pulmonary 
edema, since 24 hours after administration of L-NAC, the 
LB ratio was similar to that in other experimental groups 
and remained such until the 6th day (Table 3). Here, one 
can talk of the protective effect of L-NAC in this form of 
the aspiration lung injury.
Acute lung injury caused by intratracheal administra-
tion of acidin-pepsin solution caused not as a pronounced 
increase in the LB ratio as when using acetone. The LB 
ratio in control group was almost the same both 24 hours 
and 6 days later (Table 4). The use of dexamethasone and 
hyperosmolar solutions led to an increase in pulmonary 
edema, rather than a decrease in it, although those values 
did not have statistically significant differences relative 
to the control group. The combination therapy of dexa-
methasone and HS used on this model reduced the de-
gree of pulmonary edema very effectively. The LB ratio 
with this therapy did not differ from that of normal lungs 
and was smaller than with applying a monotherapy with 
hyperosmolar solutions and dexamethasone separately. 
The LB ratio on the 6th day in the group with HS+Dex 
was comparable to that in the healthy animals, which 
also confirms the effectiveness of this combination for 
the treatment of pulmonary edema (Table 4). Liposomal 
forms of aprotinin and dexamethasone also performed 
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Table 3. Rats’ lung-body ratio in acute lung injury caused by aspiration of acetone after using experimental therapeutic agents 
(M±m, n=10).
Time Groups of experimental therapy
Control Dexametasone HS HyperHAES L-NAC Intact animals
24 hours 13.4±0.9 
р1<0.001
8.6±1.1 
р2<0.05
11.2±0.7 
р1<0.001
7.63±0.6 
р2<0.01 
p4<0.05
8.5±0.6 
р1,4<0.05 
р2<0.01
 7.0±0.2
6 days – 11.1±0.5 
р1<0.001
11.5±0.7 
р1<0.001
10.5±0.4 
р1<0.001
8.9±0.4 
р1<0.01 
р3,4,5<0.05
Note: p1 – significance of differences, calculated in relation to the group of intact animals; p2 – in relation to control group 1 (acetone 
intratracheally); p3 – in relation to the group with dexamethasone once intravenously; p4 – in relation to the group with hypertonic saline 
once intravenously; р
5
 – in relation to the group with HyperHAES once intravenously; HS – hypertonic saline; L-NAC – liposomal NAC.
Table 4. Rats’ llung-body ratio in acute lung injury caused by aspiration of acidin-pepsin after using experimental therapeutic agents 
(M±m, n=10).
Time Groups of experimental therapy
Control Dexa- 
metasone
HS Hyper 
HAES
L-aprotinin HLD HS+Dex Intact 
animals
24 hours 9.7±0.5 
р1<0.01
11.0±2.0 
р1<0.05
11.9±3.3 
р1<0.05
12.3±0.6 
р1<0.001 
р2<0.05
8.2±0.6 
р1<0.05 
р
5
<0.01
5.3±0.3 
р1,4<0.001 
р2,3<0.05 
р
5,6
<0.01
6.4±1.1 
р2<0.05 
р
5
<0.01
 7.0±0.2
6 days 9.8±1.0 
р1<0.05
11.4±1.6 
р1<0.01
12.3±0.9 
р1<0.001
14.7±0.8 
р1<0.001 
р2<0.05
7.3±1.0 
р4,5<0.01
7.6±1.5 
р4,5<0.05
7.5±1.4 
р4<0.05 
р
5
<0.01
Note: p1 – significance of differences, calculated in relation to the group of intact animals; p2 – in relation to control group 1 (aci-
din-pepsin intratracheally); p3 – in relation to the group with dexamethasone once intravenously; p4 – in relation to the group with 
hypertonic saline once intravenously; р
5
 – in relation to the group with HyperHAES once intravenously; р6 – in relation to the group 
with liposomal aprotinin once intravenously; HS – hypertonic saline; HLD – hyperosmolar liposomal dexamethasone; HS+Dex – 
dexamethasone in combination with hypertonic (7.5%) sodium chloride solution.
well on this model. L-aprotinin 24 hours later reduced 
the degree of pulmonary edema in a more pronounced 
way than HyperHAES. In the group with HLD 24 hours 
later, the LB ratio was the lowest. Six days later, the 
lungs of the animals after the use of liposomal forms 
of aprotinin and dexamethasone had the LB ratio at the 
same level as in intact rats.
Thus, on the 6th day, the LB ratio in the animals trea-
ted with liposomal forms approached the value of healthy 
lungs in two ALI models.
Discussion
During 6 days of the observation after aspiration of ace-
tone, the lowest mortality rate was observed in rats that 
had received an intravenous injection of liposomal NAC. 
However, the greatest difference was in relation to the 
group in which no experimental therapy had been used, 
which means that all the proposed schemes are a way to 
reduce the mortality rate in case of aspiration of acetone.
The SpO2 level recovered in all the animals that had 
survived until the 6th day to a level that did not differ 
statistically, whereas the level remained lower than that 
observed in the healthy animals. This suggests that the 
recovery of the respiratory function had a similar posi-
tive trend, regardless of a type of the drug substance. 
Since the RR in rats with ALI fluctuated unevenly, its 
changes cannot be attributed to the causes of morta-
lity and a decrease of blood oxygen saturation in this 
study. The fact that on the 6th day after the aspiration 
of acidin-pepsin the blood oxygenation in the control 
group with ceftriaxone-based supporting therapy rose to 
86.7±2.2% can mean that the recovery of the respiratory 
function 6 days after the start of the experiment hardly 
depends on a single injection of the tested drugs, and 
the main influence was made by the daily administration 
of ceftriaxone, preventing the development of purulent 
aspiration pneumonia.
The use of liposomal aprotinin can be considered an 
effective remedy for ALI. Perhaps high efficiency of 
liposomal aprotinin is associated with its antiproteolytic 
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properties and a liposomal form, which ensured survival 
within the ALI acute period up to 73.4% and a low LB 
ratio on the 1st and 6th days, which indicates effective 
prevention of pulmonary edema. When comparing the 
pathological manifestations of the two models used, it 
can be said that acidin-pepsin exerted its damaging ef-
fect more slowly, which was due to the fact that unlike 
acetone, acidin-pepsin acted as a result of proteolysis of 
the pulmonary tissue protein structures. Proteolysis had 
already led to the destruction of the lung tissue. The fea-
ture of the pathogenesis of the ALI model showed in the 
effectiveness of the applied therapy. The reference the-
rapy with dexamethasone would not lead to significant 
reductions in the manifestations of ALI, while the effect 
of liposomal aprotinin would lead to a positive change 
not on the 1st, but on the 6th day, which confirms the ef-
fectiveness of liposomal aprotinin in this model.
Taking into account the survival rate of the animals by 
the 6th day of the experiment, it can be concluded that the 
liposomal form of dexamethasone in the hypertonic NaCl 
solution proved to be an effective means for controlling as-
piration of acidin-pepsin. HLD ensured high pharmacolo-
gical efficacy in ALI. It may have been due to the peculiar 
release of dexamethasone from liposomes and an additio-
nal osmotic effect of 7.5% NaCl. In the form of monothe-
rapy, HS also ensured a high survival rate of the animals 
in this model of ALI. A marked therapeutic effects of HLD 
can be due, first, to the peculiarities of drug release, which, 
like other membrane structures (erythrocytes) respond 
to changes in the environmental osmolarity. In this case, 
with intravenous administration, the environment around 
liposomes became isotonic, while the liposome content - 
was hypertonic. Under the influence of diffusion forces, 
dexamethasone along with hypertonic saline could be re-
leased from liposomes into blood (Monteiro et al. 2015). 
However, to prove this, more research is needed. Secondly, 
the reason of high efficiency of HLD may be related to the 
lecithin which is part of liposomes. Phosphatidylcholine, 
as the main component of liposome vesicles, exhibit surfa-
ce active properties and, thus, can prevent the collapse of 
alveoli in ALI (Rugonyi et al. 2008).
The specific mechanisms of the positive effect of 
phosphatidylcholine on lung tissue remain unclear. Ho-
wever, a number of studies make the picture more obvi-
ous. In particular, Gwinn et al. (2011) showed that sur-
face-active properties of phosphatidylcholine promote 
apoptosis of neutrophils and, as a consequence, reduce 
the severity of pneumonia. There is also evidence that 
indicate a positive effect of liposomal lipids on ventila-
tion, a histopathological picture and a surfactant levels 
in laboratory animals with ALI (Rugonyi et al. 2008). 
Liposomal lipids can exert an antioxidant effect, as they 
take part in oxidation processes, protecting cell membra-
nes from oxidation (Meng and Xu 2015).
HLD therapy turned out to be the most effective for 
preventing the development of pulmonary edema. The 
advantage of HLD therapy over the reference HS+-
Dex-based therapy was observed on the 1st and 6th days 
of the experiment. Thus, liposomal dosage forms used 
for treatment of acidin-pepsin aspiration model showed 
a higher therapeutic efficacy compared to that in the 
other regimens. Hypertonic solutions affected a degree 
of pulmonary edema in both ALI models in a way which 
was comparable to the treatment with dexamethasone at 
the stated dose.
Looking at the kinetics of the in vivo distribution of 
liposomes, it can be noted that it depends on the ex-
pected size of liposomes used and is consistent with 
some literature data (Li et al. 2017), describing the 
dependence of the biodistribution of nanoparticles in-
jected intravenously on their size. Liposomes used in 
the study were large enough, whose vesicle size ran-
ged within 350 nm. Liposomes were simple and con-
tained a membrane of phospholipids, and, therefore, 
could quickly undergo biodegradation under the action 
of enzyme systems, blood and tissues (Meng and Xu 
2015). Considering that the concentration of the free 
dye in blood within one hour after the administration 
did not significantly fluctuated, it can be concluded that 
liposomes, as carriers of a drug substance, better than a 
dissolved form ensure accumulation of the drug in in-
ternal organs, primarily lungs. If the accumulation of 
the liposomal form of Cy-7 increased in the lungs after 
intravenous administration, simultaneously its content 
reduced in the liver and kidneys. The liver showed itself 
as a primary concentrator of the dye administered intra-
venously, regardless of its form. The liver accumulated 
the solute more actively, while the liposomal substance 
in liposomal vesicles of about 350 nm accumulated lon-
ger in the lungs. Including the substance into liposomes 
was aimed at creating its high concentration in the lung, 
as a result of intravenous administration. The goal was 
achieved by using liposomes of the appropriate size. By 
means of liposomes, the substance after intravenous ad-
ministration could contact more with lung tissue, which 
was a target for the therapy in the current study, and less 
with the liver, which is the main organ for metabolizing 
and inactivating the drug.
Conclusion
The experimental results showed good perspectives 
of parenteral use of liposomal drug forms containing 
N-acetylcysteine, aprotinin, dexamethasone, as well as 
hyperosmolar solutions based on sodium chloride, as 
means to correct the main pathological manifestations 
of acute lung injury.
The identified features of biodistribution of liposomes 
with a diameter of about 350 nm justify the intravenous 
administration of liposomal forms to increase the accu-
mulation of drugs in the lungs when treating ALI.
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